from Pharma Live about a survey of oncologists and urologists "reveals a lack of awareness and understanding of the clinical benefits of Combined Androgen Blockade (CAB) therapy for the management of advanced prostate cancer." Why is that a CME issue? Check this out:
Mr David Gillatt, a panel member and Consultant Urologist at Southmead Hospital, Bristol, UK commented that: "In this era of targeted therapies and evolving innovations in healthcare and specifically prostate cancer, it is the new drugs that dominate proceedings at medical meetings and secure interest. We must not allow the benefits of established and proven treatments, such as CAB, to be overlooked to the detriment of patient care."
I don't know for a fact, but I would hazard a guess that this issue extends beyond prostate cancer care to many disease states. While it's understandable to focus on the latest whiz-bang treatments (that is, after all, what grabs newspaper headlines after national society meetings, and what docs are coming to hear about), be sure your faculty doesn't forget to mention less sexy but still effective therapies.